ArticleAsiaIntervention2026
Pulmonary artery denervation improves left ventricular diastolic function in patients with isolated post-capillary pulmonary hypertension secondary to heart failure with preserved ejection fraction: a safety and proof-of-principle cohort study.
Article in AsiaIntervention, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06323512 (Pulmonary Artery Denervation for Treatment of Patients With Heart Failure Without Pulmonary Hypertension), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pulmonary Artery Denervation for Treatment of Patients With Heart Failure Without Pulmonary Hypertension: a Safety and Proof-of-principle Cohort Study
Who cites it
2 citing papers in PubMed.
- Novel device-based and catheter-directed therapies for heart failure with preserved ejection fraction.Cardiovascular intervention and therapeutics · 2026Review
- Flipping the focus - treating post-capillary pulmonary hypertension with pulmonary artery denervation.AsiaIntervention · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The benefits of pulmonary artery denervation (PADN) for patients with isolated post-capillary pulmonary hypertension (IpcPH) secondary to left heart failure with preserved ejection fraction (HFpEF) remain unknown. Aims: This study aimed to evaluate the safety and feasibility of PADN in patients with HFpEF-induced IpcPH. Methods: This was a single-centre, proof-of-principle cohort study conducted in China. Patients with chronic HFpEF (>=6 months), receiving guideline-directed medical therapy for >=3 months, and meeting criteria for stage C heart failure and IpcPH were included. Eligible patients had New York Heart Association Class III or ambulatory Class IV symptoms and a plasma N-terminal prohormone B-type natriuretic peptide level >300 pg/mL. Right heart catheterisation was performed to assess haemodynamics, and the rate of change of left ventricular pressure (dP/dt) was monitored for 10 minutes following the PADN procedure. Results: At 10 minutes post-procedure, PADN resulted in a 16.9% reduction in mean pulmonary arterial pressure (PAP) and a 22.9% reduction in pulmonary artery wedge pressure (PAWP), with no significant changes in cardiac output, right atrial pressure, or pulmonary vascular resistance. Additionally, the minimum left ventricular dP/dt (dP/dtmin) significantly decreased from -1,698.9±322.9 mmHg/s at baseline to -2,048.0±442.3 mmHg/s (a 20.5% reduction; p=0.012), indicating improved left ventricular relaxation. However, the maximum dP/dt and left ventricular end-systolic pressure remained unchanged. Conclusions: PADN is associated with significant reductions in PAP and PAWP, likely driven by improved left ventricular relaxation, as reflected by dP/dtmin, in patients with HFpEF-induced IpcPH. ClinicalTrials.gov: NCT06323512.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.